This is a single arm, open-label, multi-center, phase II study to determine the activity and the safety of a therapeutic strategy that allows a second CARCIK-CD19 cells infusion, driven by the status of disease from one month after the first infusion, in adult and pediatric patients with r/r BCP- ALL.

Inclusion Criteria:

Children (1-17) and adults (18-75 years old);

• Relapsed or refractory adult and pediatric B- ALL as defined for the presence of bone marrow with ≥ 5% lymphoblasts by morphologic assessment, or if <5%, with at least 1% of molecular disease at PCR;
• Evidence of CD19 tumor expression in bone marrow and/or peripheral blood by flow cytometry;
• Diagnosis of CD19 positive ALL in the bone marrow, and/or peripheral blood and/or extramedullary sites with the exclusion of Central Nervous System (CNS) if CNS-3 disease.

Exclusion Criteria:

• GVHD Grades II-IV for patients who had previously been transplanted; 2. Any cell therapy in the previous 30 days;
• Patient with concomitant life-threatening infectious disease;
• Lansky/Karnofsky score <60;
• Patients with hepatic or renal disease as specific above;
• Pregnant or breast-feeding females;
• Rapidly progressive disease that in the estimation of the investigator and sponsor would compromise ability to complete study therapy;